about
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber,...
Read More
1.00
0.11
(12.36%)
98,407
XNAS Volume
XNAS 08 Aug, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Cytosorbents Corp is on 13 Aug 2025 for the purpose of CytoSorbents Corp Second Quarter Earnings Results for 2025
See details
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Cytosorbents Corp Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..